Dyne Therapeuticsinc Stock Analysis
| DYN Stock | USD 24.98 0.46 1.81% |
Dyne TherapeuticsInc is undervalued with Real Value of 27.28 and Target Price of 29.5. The main objective of Dyne TherapeuticsInc stock analysis is to determine its intrinsic value, which is an estimate of what Dyne TherapeuticsInc is worth, separate from its market price. There are two main types of Dyne TherapeuticsInc's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Dyne TherapeuticsInc's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Dyne TherapeuticsInc's stock to identify patterns and trends that may indicate its future price movements.
The Dyne TherapeuticsInc stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Dyne TherapeuticsInc is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Dyne Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Dyne TherapeuticsInc's ongoing operational relationships across important fundamental and technical indicators.
Dyne |
Dyne Stock Analysis Notes
About 87.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Dyne TherapeuticsInc recorded a loss per share of 3.95. The entity last dividend was issued on the May 30, 2002. The firm had 1:5 split on the May 25, 2010. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. Dyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. To learn more about Dyne TherapeuticsInc call Robert Flexon at 781 786 8230 or check out https://www.dyne-tx.com.Dyne TherapeuticsInc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dyne TherapeuticsInc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dyne TherapeuticsInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Dyne TherapeuticsInc had very high historical volatility over the last 90 days | |
| Reported Net Loss for the year was (235.94 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne TherapeuticsInc has about 291.84 M in cash with (188.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Dyne Therapeutics, Inc. Sees Large Increase in Short Interest - Defense World |
Dyne TherapeuticsInc Upcoming and Recent Events
Earnings reports are used by Dyne TherapeuticsInc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dyne TherapeuticsInc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Dyne Largest EPS Surprises
Earnings surprises can significantly impact Dyne TherapeuticsInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-12-31 | 2017-12-31 | -0.42 | -0.35 | 0.07 | 16 | ||
2023-03-02 | 2022-12-31 | -0.84 | -0.74 | 0.1 | 11 | ||
2021-05-06 | 2021-03-31 | -0.6 | -0.5 | 0.1 | 16 |
Dyne Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dyne TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dyne TherapeuticsInc backward and forwards among themselves. Dyne TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Dyne TherapeuticsInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Franklin Resources Inc | 2023-12-31 | 1.9 M | Logos Global Management Lp | 2023-12-31 | 1.9 M | Braidwell Lp | 2023-09-30 | 1.8 M | Wasatch Advisors Inc. | 2023-12-31 | 1.7 M | Tcg Crossover Management, Llc | 2023-12-31 | 1.7 M | Nantahala Capital Management, Llc | 2023-12-31 | 1.3 M | Fmr Inc | 2023-12-31 | 1.3 M | Artal Group S A | 2023-12-31 | 1.2 M | Vivo Capital, Llc | 2023-12-31 | 1 M | Fcpm Iii Services Bv | 2023-12-31 | 6.1 M | Mpm Asset Management, Llc | 2023-12-31 | 5 M |
Dyne Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 2.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dyne TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Dyne TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Dyne Profitablity
Dyne TherapeuticsInc's profitability indicators refer to fundamental financial ratios that showcase Dyne TherapeuticsInc's ability to generate income relative to its revenue or operating costs. If, let's say, Dyne TherapeuticsInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dyne TherapeuticsInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dyne TherapeuticsInc's profitability requires more research than a typical breakdown of Dyne TherapeuticsInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.43) | (1.36) | |
| Return On Capital Employed | (2.12) | (2.02) | |
| Return On Assets | (1.43) | (1.36) | |
| Return On Equity | (2.58) | (2.46) |
Management Efficiency
Dyne TherapeuticsInc has Return on Asset of (0.6421) % which means that on every $100 spent on assets, it lost $0.6421. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3731) %, meaning that it generated no profit with money invested by stockholders. Dyne TherapeuticsInc's management efficiency ratios could be used to measure how well Dyne TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 25th of April 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.53 | 1.45 | |
| Enterprise Value Over EBITDA | (2.92) | (2.77) | |
| Price Book Value Ratio | 8.70 | 9.13 | |
| Enterprise Value Multiple | (2.92) | (2.77) | |
| Price Fair Value | 8.70 | 9.13 | |
| Enterprise Value | 699.6 M | 465.1 M |
The analysis of Dyne TherapeuticsInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Dyne TherapeuticsInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Dyne Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.952 |
Technical Drivers
As of the 25th of April, Dyne TherapeuticsInc shows the Downside Deviation of 3.94, mean deviation of 3.37, and Coefficient Of Variation of 530.58. Dyne TherapeuticsInc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Dyne TherapeuticsInc, which can be compared to its peers. Please confirm Dyne TherapeuticsInc coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Dyne TherapeuticsInc is priced favorably, providing market reflects its regular price of 24.98 per share. Given that Dyne TherapeuticsInc has jensen alpha of 0.5586, we urge you to verify Dyne TherapeuticsInc's prevailing market performance to make sure the company can sustain itself at a future point.Dyne TherapeuticsInc Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Dyne TherapeuticsInc middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Dyne TherapeuticsInc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Dyne TherapeuticsInc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dyne TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dyne TherapeuticsInc Predictive Daily Indicators
Dyne TherapeuticsInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dyne TherapeuticsInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dyne TherapeuticsInc Corporate Filings
| 5th of April 2024 Other Reports | ViewVerify | |
13A | 4th of April 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 27th of March 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 25th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 5th of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Dyne TherapeuticsInc Forecast Models
Dyne TherapeuticsInc's time-series forecasting models are one of many Dyne TherapeuticsInc's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dyne TherapeuticsInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Dyne Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Dyne TherapeuticsInc prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dyne shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dyne TherapeuticsInc. By using and applying Dyne Stock analysis, traders can create a robust methodology for identifying Dyne entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.22) | (1.16) | |
| Operating Profit Margin | (0.94) | (0.89) | |
| Net Profit Margin | 0.17 | 0.18 | |
| Gross Profit Margin | (5.51) | (5.79) |
Current Dyne Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dyne analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dyne analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 29.5 | Strong Buy | 9 | Odds |
Most Dyne analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dyne stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dyne TherapeuticsInc, talking to its executives and customers, or listening to Dyne conference calls.
Dyne Stock Analysis Indicators
Dyne TherapeuticsInc stock analysis indicators help investors evaluate how Dyne TherapeuticsInc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dyne TherapeuticsInc shares will generate the highest return on investment. By understating and applying Dyne TherapeuticsInc stock analysis, traders can identify Dyne TherapeuticsInc position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 172.1 M | |
| Total Stockholder Equity | 91.3 M | |
| Capital Lease Obligations | 27.4 M | |
| Total Liab | 73.8 M | |
| Property Plant And Equipment Net | 33.4 M | |
| Cash And Short Term Investments | 123.1 M | |
| Net Invested Capital | 91.3 M | |
| Cash | 121.6 M | |
| 50 Day M A | 25.9712 | |
| Net Interest Income | 7.2 M | |
| Total Current Liabilities | 51.1 M | |
| Investments | 76.4 M | |
| Stock Based Compensation | 20 M | |
| Common Stock Shares Outstanding | 59.7 M | |
| Free Cash Flow | -188.9 M | |
| Other Current Assets | 6.3 M | |
| Accounts Payable | 22.9 M | |
| Net Debt | -94.2 M | |
| Depreciation | 2.5 M | |
| Other Operating Expenses | 242.2 M | |
| Non Current Assets Total | 35.7 M | |
| Liabilities And Stockholders Equity | 165.1 M | |
| Non Currrent Assets Other | -1.00 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne TherapeuticsInc guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Dyne Stock analysis
When running Dyne TherapeuticsInc's price analysis, check to measure Dyne TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dyne TherapeuticsInc is operating at the current time. Most of Dyne TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Dyne TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dyne TherapeuticsInc's price. Additionally, you may evaluate how the addition of Dyne TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Dyne TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne TherapeuticsInc. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.95) | Return On Assets (0.64) | Return On Equity (1.37) |
The market value of Dyne TherapeuticsInc is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Dyne TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne TherapeuticsInc's market value can be influenced by many factors that don't directly affect Dyne TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.